BE2018C038I2 - - Google Patents

Info

Publication number
BE2018C038I2
BE2018C038I2 BE2018C038C BE2018C038C BE2018C038I2 BE 2018C038 I2 BE2018C038 I2 BE 2018C038I2 BE 2018C038 C BE2018C038 C BE 2018C038C BE 2018C038 C BE2018C038 C BE 2018C038C BE 2018C038 I2 BE2018C038 I2 BE 2018C038I2
Authority
BE
Belgium
Prior art keywords
disease
patient
body weight
provides methods
comprises administering
Prior art date
Application number
BE2018C038C
Other languages
English (en)
French (fr)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22337648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2018C038(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BE2018C038I2 publication Critical patent/BE2018C038I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
BE2018C038C 1998-12-07 2018-09-28 BE2018C038I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11129198P 1998-12-07 1998-12-07
EP99965162A EP1137762B1 (de) 1998-12-07 1999-12-06 Behandlung der pompeschen krankheit

Publications (1)

Publication Number Publication Date
BE2018C038I2 true BE2018C038I2 (de) 2019-03-05

Family

ID=22337648

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2018C038C BE2018C038I2 (de) 1998-12-07 2018-09-28

Country Status (16)

Country Link
US (7) US20030007963A1 (de)
EP (2) EP2020438B1 (de)
JP (7) JP4990434B2 (de)
KR (1) KR20010101131A (de)
AT (1) ATE410506T1 (de)
AU (1) AU3113700A (de)
BE (1) BE2018C038I2 (de)
CA (1) CA2353522A1 (de)
CY (2) CY1121113T1 (de)
DE (2) DE122009000018I1 (de)
DK (2) DK2020438T3 (de)
ES (2) ES2677343T3 (de)
LU (1) LU91544I2 (de)
NL (1) NL300382I2 (de)
PT (2) PT1137762E (de)
WO (1) WO2000034451A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3113700A (en) * 1998-12-07 2000-06-26 Genzyme Corporation Treatment of pompe's disease
DE60138535D1 (de) * 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
AU2001271941B2 (en) * 2000-07-18 2007-03-01 Duke University Treatment of glycogen storage disease type II
EP1782825B1 (de) * 2000-07-18 2014-09-10 Duke University Behandlung der Glykogenspeicherkrankheit typ II
AU2016256663A1 (en) * 2000-07-18 2016-11-24 Duke University Treatment of clycogen storage disease type II
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ES2300439T3 (es) * 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
ATE521701T1 (de) * 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
ES2541952T3 (es) * 2003-01-31 2015-07-28 The Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
AU2005212435B2 (en) * 2004-02-10 2010-09-09 Biomarin Pharmaceutical Inc. Acid alpha-glucosidase and fragments thereof
KR100697270B1 (ko) * 2004-12-10 2007-03-21 삼성전자주식회사 저전력 멀티칩 반도체 메모리 장치 및 그것의 칩 인에이블방법
BRPI0612928A2 (pt) 2005-05-17 2010-12-07 Amicus Therapeutics Inc Método para aumentar a atividade de uma enzima de (alfa)-glucosidade em uma célula e método para tratar doença de pompe
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
BRPI0912225A2 (pt) * 2008-05-07 2018-03-20 Zystor Therapeutics, Inc. peptídeos de direcionamento lisossomais e usos dos mesmos
PL2318037T3 (pl) 2008-07-08 2015-07-31 Univ Duke Sposób leczenia Choroby Spichrzeniowej Glikogenu
EP3075386B1 (de) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
US8536148B2 (en) 2009-09-04 2013-09-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Disabling autophagy as a treatment for lysosomal storage diseases
PL3205351T3 (pl) 2010-04-23 2023-08-28 Alexion Pharmaceuticals, Inc. Enzym na lizosomalną chorobę spichrzeniową
KR102537084B1 (ko) 2010-06-25 2023-05-26 샤이어 휴먼 지네틱 테라피즈 인크. 아릴설파타제 a의 cns 전달을 위한 방법들 및 조성물들
US8545837B2 (en) 2010-06-25 2013-10-01 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
US9320711B2 (en) 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
WO2011163648A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
HUE031036T2 (en) 2010-06-25 2017-06-28 Shire Human Genetic Therapies Therapeutic drug delivery to the central nervous system
MX2013000324A (es) 2010-06-25 2013-02-01 Shire Human Genetic Therapies Tratamiento del sindrome de sanfilippo tipo b.
CA2810999C (en) 2010-09-09 2023-10-03 Anthony Quinn Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
US9493753B2 (en) 2011-03-16 2016-11-15 Amano Enzyme Inc. Modified α-glucosidase and applications of same
CA2833371A1 (en) * 2011-04-22 2012-10-26 Genzyme Corporation Modified acid alpha glucosidase with accelerated processing
EP2793922B1 (de) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stabile formulierungen zur verabreichung von arylsulfatase a in das zns
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
EP2981551B1 (de) 2013-02-20 2020-06-03 Valerion Therapeutics, LLC Verfahren und zusammensetzungen zur behandlung von morbus pompe
WO2016025523A1 (en) 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
KR20220146662A (ko) 2014-09-30 2022-11-01 아미쿠스 세라퓨틱스, 인코포레이티드 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
EP3344337A4 (de) * 2015-08-31 2019-03-06 Duke University Verfahren und zusammensetzungen zur behandlung von zytoplasmatischen glycogenspeichererkrankungen
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017117407A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
WO2017173059A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
IL283430B (en) 2016-03-30 2022-07-01 Amicus Therapeutics Inc Formulations that include recombinant acid alpha-glucosidase
EP3293260A1 (de) 2016-09-12 2018-03-14 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
EP3293203A1 (de) 2016-09-12 2018-03-14 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
EP3510149A1 (de) 2016-09-12 2019-07-17 Genethon Saure alpha-glucosidase-varianten und verwendungen davon
US20220331408A1 (en) 2019-07-09 2022-10-20 Genethon Treatment of glycogen storage disease (gsd)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832981A1 (de) * 1987-02-17 1998-04-01 Pharming B.V. DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
DK0502976T3 (da) 1989-12-01 1996-11-11 Pharming Bv Produktion af rekombinante polypeptider ved bovine arter og transgene fremgangsmåder
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
EP0652889A4 (de) * 1992-06-15 1997-05-07 Gene Pharming Europ Bv Herstellung von rekombinantpolypeptiden durch runderarten und transgene verfahren.
EP0625530A1 (de) * 1993-05-17 1994-11-23 Nippon Paint Co., Ltd. Oxazolidongruppen enthaltende Epoxidharze- und diese enthaltende kathodische Elektrotauchlacke
AT1470U1 (de) 1995-08-01 1997-05-26 Austria Card Laminierte karte und verfahren zu ihrer herstellung
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AU3113700A (en) * 1998-12-07 2000-06-26 Genzyme Corporation Treatment of pompe's disease

Also Published As

Publication number Publication date
EP1137762A1 (de) 2001-10-04
US20040081645A1 (en) 2004-04-29
EP1137762B1 (de) 2008-10-08
DE69939705D1 (de) 2008-11-20
PT1137762E (pt) 2009-01-14
JP2012224643A (ja) 2012-11-15
CY2018020I2 (el) 2019-07-10
DK1137762T3 (da) 2009-02-02
LU91544I2 (fr) 2009-05-25
EP2020438B1 (de) 2018-04-11
US7351410B2 (en) 2008-04-01
US20140037611A1 (en) 2014-02-06
WO2000034451A1 (en) 2000-06-15
US20080206223A1 (en) 2008-08-28
JP2018115200A (ja) 2018-07-26
JP2009161562A (ja) 2009-07-23
NL300382I2 (en) 2009-12-01
JP2017066160A (ja) 2017-04-06
CA2353522A1 (en) 2000-06-15
ES2312222T3 (es) 2009-02-16
AU3113700A (en) 2000-06-26
US20160243203A1 (en) 2016-08-25
EP1137762A4 (de) 2005-01-12
DE122009000018I1 (de) 2009-09-17
JP4990434B2 (ja) 2012-08-01
ES2677343T3 (es) 2018-08-01
JP2002531581A (ja) 2002-09-24
CY2018020I1 (el) 2019-07-10
DK2020438T3 (en) 2018-07-23
US20030007963A1 (en) 2003-01-09
US7655226B2 (en) 2010-02-02
JP2019172685A (ja) 2019-10-10
US20130039901A1 (en) 2013-02-14
CY1121113T1 (el) 2019-07-10
KR20010101131A (ko) 2001-11-14
US20100092449A1 (en) 2010-04-15
NL300382I1 (nl) 2009-06-02
JP2015134836A (ja) 2015-07-27
ATE410506T1 (de) 2008-10-15
PT2020438T (pt) 2018-07-13
EP2020438A1 (de) 2009-02-04

Similar Documents

Publication Publication Date Title
BE2018C038I2 (de)
GB8712073D0 (en) Medicament
NZ514077A (en) Treatment of Α-galactosidase A deficiency
GR3030867T3 (en) Guanidine derivatives useful in therapy
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
PL309594A1 (en) Apllication of rilusole in treating parkinson disease and parkinsonian syndromes
ZA95679B (en) Products containing G-CSF and TNF binding protein
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
EP1006793A4 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
EP0437929A3 (en) Use of diadenosine-5',5'''-p1,p4-tetraphosphate for the manufacture of a medicament for the treatment of heart disease
UA41329C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії
GR3032224T3 (en) Therapeutic agent for threatened abortion.
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
GR3022608T3 (en) USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE.
NZ268039A (en) Use of efaroxan in treating parkinson's disease
ZA941816B (en) Benzimidazole derivatives their preparation and use
EP0353910A3 (en) Human interferon-gamma, process for preparing said human interferon-gamma, and its use
AU616657B2 (en) Butyl hydroxyanisoles for the treatment of retroviral diseases
Rakel Antihypertensive therapy and quality of life
UA10301A (uk) Спосіб лікуваhhя раку шлуhку
MD1469G2 (ro) Metodă de tratament al şocului combustional
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору